CCDC163

Across TCGA pan-cancer cohorts, CCDC163 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of CCDC163’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CCDC163 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CCDC163 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

KIRC, LIHC, and THCA are the cancer types where CCDC163 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CCDC163 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.456	<.001	11	view →
LIHC	Female	II,III,IV	+1.233	<.001	9	view →
THCA	All	All	−0.639	<.001	7	view →
STAD	All	II,III,IV	+0.718	<.001	6	view →
LUSC	All	II,III,IV	+0.583	<.001	6	view →
LUAD	All	All	+0.536	<.001	6	view →
HNSC	All	III,IV	+0.470	.004	6	view →
COAD	All	II,III,IV	+0.375	.001	4	view →
CHOL	Male	All	+1.991	<.001	3	view →
BRCA	All	All	+0.233	.019	3	view →
BLCA	All	All	+0.576	.036	2	view →
KICH	All	All	−0.530	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

CCDC163–KIRC

Open the KIRC breakdown →